Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. - Test2 - elhamkhani - TriplyDB

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

http://www.wikidata.org/entity/Q35720774

about

PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk Investigation of serum proteome alterations in human glioblastoma multiforme.Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response.MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Delayed epidural transplantation of human induced pluripotent stem cell-derived neural progenitors enhances functional recovery after stroke.Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3 Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.Defining the pathway to insulin-like growth factor system targeting in cancer.FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.Metabolic imbalance and prostate cancer progression.The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.IGFBP-2 - taking the lead in growth, metabolism and cancer Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.Insulin-like growth factor binding protein 2 promotes glioma development and progression Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation.IGFBP2 potentiates nuclear EGFR-STAT3 signaling.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice.

P2860

Q24309255-31C92B7D-33C7-44D0-BD47-CD5CCA97B906 Q24315972-B1A5CD4F-16A5-4BCB-80D2-C57A6D8E1BD3 Q24600470-7DE6AAF0-9E2E-44F4-BF94-B0DC71974EE7 Q27003443-E0769C44-B56D-4D6D-9B3B-370CD3B755E3 Q28240702-51C77970-E724-49CF-854E-CDE967FEE88D Q28261810-56F065BA-6461-4C3F-9651-9C94CFED1E8E Q30384833-23126CC4-B6FD-43F7-AE7D-F669A44FCECA Q30402547-68FDC8C6-45E7-46BB-AE9F-A6599CAAD3DB Q30440601-6C27533F-F100-4748-8001-D19ABCEE774C Q31049602-2015264A-799B-44D1-A590-08196A56C88A Q31063977-F3B588A3-DC45-4E87-9B94-6F505CD1F2C9 Q33352317-3DF902E3-A872-47EE-8C17-26CAF6E7AD4D Q33495847-EA8D8ED0-2380-4952-94C6-896FFCC1B911 Q33527586-3A0F1B08-E649-4466-A815-7AB16A2968A6 Q33579323-C88C1F79-3293-49F8-8446-69B0164E0574 Q33612132-020A4AB7-3331-4B08-9A3A-796668985A0E Q33694696-1F15CA2D-AD2B-45D2-8AD1-2FD22D7F3DF9 Q33745176-8D6A3A29-20A8-4991-A96C-1C5C799A5ABE Q33852403-4C16E943-8949-4B4E-A210-4495C0829D9B Q33915813-602731D5-516B-436B-92DB-22F8EF5297DF Q34107722-73C1DC7B-275B-40E1-B841-F7E58C6B755D Q34310561-746CB0E4-450C-43F2-ADFA-B6954EB83A11 Q34602348-3067D7EB-999F-433B-A739-3F224971F4AE Q34722434-4D9DDA66-A970-41C5-913D-C504B864DE2F Q34794028-14F5DBDB-AEE8-4B90-9F03-4195DAD472C8 Q34800544-C5AFCFEB-8665-419B-8DDE-CFE5F2ADC1B8 Q34986181-E9D75CC5-5B82-4CDD-8543-2F6E2EBD8E7C Q34999407-40B597C4-3292-49FB-8E22-B035815C3BC1 Q35474529-6578A90B-DFBE-4671-B32F-1BBB9516E20D Q35633850-72067527-F362-4E96-AA6B-4024195033C6 Q35690628-402F37E5-0F0D-4C26-99DE-AF4190F68BE6 Q35737963-3DE3BB48-C1BF-4A5D-A123-052F2A38DEB6 Q35770894-E05D4276-F4F6-4E9F-BD9F-AE5F98CF638F Q35836632-1D561761-26D6-437B-B71B-F02D55CCBA44 Q35880328-8DDF3EBA-1670-42FD-B493-5905876ED83E Q36064698-9BD705D2-0317-49C6-8608-C95EB5D0F29C Q36189855-5BC26D11-4546-4429-B8E3-1546322BBE48 Q36199762-2383312D-EB21-4C1A-9086-B065DF58A7A4 Q36214062-72894CDD-0ACD-4DD9-8FB6-0AC283CAE87A Q36578780-41D31572-F9FE-4E02-83D2-78199C0697B5

P2860

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

http://www.wikidata.org/entity/Q35720774

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@ast

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@en

type

label

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@ast

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@en

prefLabel

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@ast

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@en

P1433

Q35720774-65CA0506-E808-4932-B386-C5CFB84C5AB1

P1476

Q35720774-31BD3AA5-6887-4132-AFDD-44D78A972C52

P2093

Q35720774-2ADC3D4B-B3E5-4609-A648-997CE0F7A376

Q35720774-3903ECC8-1BE1-42C8-95B3-6B0C17D1DF33

Q35720774-5314DA0B-7F6F-4ABC-85D3-11258B5CC3B8

Q35720774-5AB525FD-FF22-4829-935E-0F3AF3FE67C9

Q35720774-918DDF6D-88A6-49B7-BCE4-5745B1424312

Q35720774-CCC3BA31-1F7A-4267-937B-13D9271E7CFA

Q35720774-F27F1C9A-267A-40A9-88B1-CC162CFCC72C

P2860

Q35720774-05011F55-792F-4B8D-838B-E5E4037E11CD

Q35720774-10967877-FAFE-49A4-AE37-77B86D49CC02

Q35720774-148AA8D6-0E7B-4B9A-AACF-5F3402FF89EA

Q35720774-1DFF8304-6EC4-402E-B7F4-AEAEAFA87179

Q35720774-1F59E7F8-7ABC-494F-9DF8-C04999395CE1

Q35720774-207D160C-53A3-40BA-AFC9-1AEB453F2DCA

Q35720774-3493F25F-76EC-420F-A9AE-2A1CD1D84EBF

Q35720774-39FB44BC-13D7-47B3-A45F-A7DB182B9B1D

Q35720774-3F0CC63B-764D-4ACE-8C89-FEB3B8370522

Q35720774-4C93230E-6445-438F-8AF4-C4785C93CB06

P304

Q35720774-FDFDE851-8FE2-4C27-BA51-118483A0FB26

P31

Q35720774-5799831F-65A8-4922-8391-EAF143D16E30

P356

Q35720774-7CCEC9BB-EB91-4999-9E15-A1E89001A372

P407

Q35720774-94A273CF-27C5-49EE-8D6B-2DBA021BCC0F

P433

Q35720774-2AC447FF-19C2-435D-BD96-E9A464B09548

P478

Q35720774-5DDDE4C3-D255-4F33-B685-0E95500B649A

P577

Q35720774-94E82482-5095-4C77-88D2-6083D3C1735D

P5875

Q35720774-5D419030-DF40-41D4-A990-D19C3E2D3465

P698

Q35720774-2833C939-2935-43DF-9CAE-861989F73BD7

P921

Q35720774-D4829637-E5A8-4341-BDDC-AB8459BF1069

Q35720774-ED8511BF-A827-418A-9500-B10674460AF8

P932

Q35720774-DEF5F445-03DB-45DB-B2EA-6D38D5F9F954

P356

PNAS.0609139104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Insulin growth factor-binding ...... oblastoma and prostate cancer.

@en

P2093

C D Chen

http://www.w3.org/2001/XMLSchema#string

C L Sawyers

http://www.w3.org/2001/XMLSchema#string

J K V Reichardt

http://www.w3.org/2001/XMLSchema#string

R Mehrian-Shai

http://www.w3.org/2001/XMLSchema#string

S F Nelson

http://www.w3.org/2001/XMLSchema#string

S Horvath

http://www.w3.org/2001/XMLSchema#string

T Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Ca2+/Calmodulin reverses phosphatidylinositol 3,4, 5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

Molecular determinants of resistance to antiandrogen therapy

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

Pten is essential for embryonic development and tumour suppression

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

P304

5563-5568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0609139104

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6435597

http://www.w3.org/2001/XMLSchema#string

P698

17372210

http://www.w3.org/2001/XMLSchema#string

P921

P932

1838515

http://www.w3.org/2001/XMLSchema#string